The CEO outlined a multi-pronged, scalable growth strategy for GLP-1s: a new oral product (Foundo) with superior accessibility, a large ex-US opportunity (e.g., 0.5% penetration in China), expansion via Medicare coverage, and a pipeline of future incretins. Foundo's small-molecule chemistry allows for massive, global supply that injectable peptides cannot match, addressing a key barrier to market expansion. The company is executing against "the most significant opportunity that's ever presented itself to the pharmaceutical industry." The combination of product diversification, scalable manufacturing, and vast untapped global demand positions Eli Lilly for sustained sales growth and industry leadership in the obesity/weight management category, supporting a long-term bullish view. Policy changes (e.g., MFN legislation) that disrupt pricing, or failure to execute on manufacturing and commercial launch scalability.